Clinical efficacy and safety of bevacizumab in combination with chemotherapy in the treatment of recurrent ovarian cancer by retrospective analysis
10.13699/j.cnki.1001-6821.2015.15.010
- VernacularTitle:回顾性分析贝伐单抗联合化疗治疗复发性卵巢癌的临床疗效及安全性评价
- Author:
Yang LI
1
;
Yang YANG
;
Yu-Min SHANG
;
Hong ZHENG
Author Information
1. 天津医院 妇产科
- Keywords:
bevacizumab;
chemotherapy;
recurrence ovarian cancer;
efficacy;
adverse drug reaction;
survival
- From:
The Chinese Journal of Clinical Pharmacology
2015;(15):1500-1502
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of bevacizumab combined with chemotherapy in the treatment of recurrence ovarian cancer.Methods Thirty seven ovarian cancer patients with complete data who treated with bevacizumab combined with chemotherapy were reviewed from the data bases of our hospital and included in this retrospective study.All included patients received more than 2 cycles of bevacizumab based combination therapy with eligible for the efficacy and toxicity assessments.The objective response rate was recorded and evaluated according to the response evaluation criteria in solid tumors (RECIST) and cancer antigen 125 (CA125) criteria.The data of survival time and adverse drug reactions were analysised . Results After treatment, the objective response rate were 32.4%and 43.2%respective-ly by the RECIST criteria and CA125 criteria.The median progression free survival for the 37 cases was 5.4 months.The two complete response patients had longest DFS interval with one for 10.0 months and another for 11.2 months.The main hematologic toxicity and non-hematologic toxicity were gradeⅠ-Ⅱneutropenia, thrombocytopenia, nausea and vomiting et al.Conclusion With acceptable toxicity and relative well clinical activity, the bevacizumab combined chemotherapy can be a potential treatment modality for the recurrent or platinum-refractory ovarian cancer.
